234 related articles for article (PubMed ID: 18806070)
1. Does preoperative level of antithrombin III predict heparin resistance during extracorporeal circulation?
Rodríguez-López JM; del Barrio E; Lozano FS; Muriel C
Anesth Analg; 2008 Oct; 107(4):1444-5. PubMed ID: 18806070
[No Abstract] [Full Text] [Related]
2. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
[TBL] [Abstract][Full Text] [Related]
3. Antithrombin III. Key factor in extracorporeal circulation.
Ranucci M
Minerva Anestesiol; 2002 May; 68(5):454-7. PubMed ID: 12029263
[TBL] [Abstract][Full Text] [Related]
4. Relationships between antithrombin activity, anticoagulant efficacy of heparin therapy and perioperative variables in patients undergoing cardiac surgery requiring cardiopulmonary bypass.
Muedra V; Bonanad S; Gómez M; Villalonga V; Sánchez F; Llopis JE
Perfusion; 2011 Nov; 26(6):487-95. PubMed ID: 21665912
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
[TBL] [Abstract][Full Text] [Related]
6. Heparin resistance and Marfan syndrome: is there any correlation?
Choudhury M; Kiran U; Saxena N; Saxena R
J Cardiothorac Vasc Anesth; 2002 Feb; 16(1):75-9. PubMed ID: 11854884
[No Abstract] [Full Text] [Related]
7. Antithrombin deficiency in special clinical syndromes--Part II: panel discussion #2.
Sacher R
Semin Hematol; 1995 Oct; 32(4 Suppl 2):67-71. PubMed ID: 8821213
[No Abstract] [Full Text] [Related]
8. [Heparin resistance during cardiopulmonary bypass].
Maeda R; Fukuda H; Nakaigawa Y; Hiruta M; Hirabayashi Y; Seo N
Masui; 2003 Sep; 52(9):1003-5. PubMed ID: 14531265
[TBL] [Abstract][Full Text] [Related]
9. Heparin resistance during cardiopulmonary bypass.
Jung HJ; Kim JB; Im KS; Oh SH; Lee JM
J Cardiovasc Med (Hagerstown); 2009 Dec; 10(12):940-1. PubMed ID: 19617851
[TBL] [Abstract][Full Text] [Related]
10. Factor VIIa-Antithrombin complexes during cardiac surgery using cardiopulmonary bypass.
Davidson SJ; Woodhams B
Int J Lab Hematol; 2011 Dec; 33(6):614-6. PubMed ID: 21569219
[TBL] [Abstract][Full Text] [Related]
11. Heparin resistance.
Bharadwaj J; Jayaraman C; Shrivastava R
Lab Hematol; 2003; 9(3):125-31. PubMed ID: 14521318
[TBL] [Abstract][Full Text] [Related]
12. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery.
Lemmer JH; Despotis GJ
J Thorac Cardiovasc Surg; 2002 Feb; 123(2):213-7. PubMed ID: 11828278
[TBL] [Abstract][Full Text] [Related]
13. Changes of antithrombin III and antithrombin III-heparin complex levels, and ACT in cardiac surgery.
Inada E; Iwahashi K; Aoki K; Takanashi S; Kohama M; Aoki Y
Can J Anaesth; 1990 May; 37(4 Pt 2):S75. PubMed ID: 2361314
[No Abstract] [Full Text] [Related]
14. [Antithrombin III substitution for optimization of the heparin effect during extracorporeal circulation in heart surgery].
Dietrich W; Schroll A; Göb E; Barankay A; Richter JA
Anaesthesist; 1984 Sep; 33(9):422-7. PubMed ID: 6496919
[TBL] [Abstract][Full Text] [Related]
15. Heparin and antithrombin III levels during cardiopulmonary bypass: correlation with subclinical plasma coagulation.
Hashimoto K; Yamagishi M; Sasaki T; Nakano M; Kurosawa H
Ann Thorac Surg; 1994 Sep; 58(3):799-804; discussion 804-5. PubMed ID: 7944706
[TBL] [Abstract][Full Text] [Related]
16. Heparin resistance, antithrombin III treatment, and activated clotting time values.
Kanbak M
Anesth Analg; 1998 Nov; 87(5):1215. PubMed ID: 9806721
[No Abstract] [Full Text] [Related]
17. [Activated coagulation time during surgery with extracorporeal circulation].
Piatnitskaia GKh; Khodaz MIa; Savina ME; Dement'eva II
Anesteziol Reanimatol; 1991; (5):66-74. PubMed ID: 1767969
[No Abstract] [Full Text] [Related]
18. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass.
Finley A; Greenberg C
Anesth Analg; 2013 Jun; 116(6):1210-22. PubMed ID: 23408671
[TBL] [Abstract][Full Text] [Related]
19. Heparinless cardiopulmonary bypass revisited: a newer strategy to avoid heparin-related bleeding using dermatan sulfate.
Brister SJ; Buchanan MR
J Cardiothorac Vasc Anesth; 1995 Jun; 9(3):317-21. PubMed ID: 7669967
[No Abstract] [Full Text] [Related]
20. An investigation of a new activated clotting time "MAX-ACT" in patients undergoing extracorporeal circulation.
Leyvi G; Shore-Lesserson L; Harrington D; Vela-Cantos F; Hossain S
Anesth Analg; 2001 Mar; 92(3):578-83. PubMed ID: 11226081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
